The authors hypothesized that the administration of anti-peptide anti-sera precomplexed with FSH or active immunization of breeding animals with these peptides should result in a superovulatory response, and that the potentiating anti-sera strategy, in the case of FSH, could be used for several clinical situations, such as treatment of ovarian disorders related to low FSH secretion, induction of estrus and treatment leading to increase spermatogenesis. The gene discussed is BRD2; the disease is ovarian disorder.